A 28-year-old woman presents with weight gain and a milky-white discharge from her breasts. Patient says she noticed herself gaining weight and a milky white discharge from her breasts. Past medical history is significant for schizophrenia, recently diagnosed and treated with risperidone. No history of headache, nausea, and vomiting. No other current medications. Her last menstrual period was 2 months ago. Review of systems is significant for decreased libido. Patient is afebrile and vital signs are within normal limits. On physical examination, patient had a weight gain of 3 kg (6.6 lb) over the past month. There is bilateral breast tenderness present. A urine pregnancy test is negative. Which of the following is the most likely etiology of this patient’s symptoms?
Q212
A 26-year-old man is brought to the emergency department by his friends because of blurred vision and slurred speech for the past 6 hours. He had some difficulty swallowing his food during lunch and has weakness in both arms. Two weeks ago, he had an upper respiratory infection that resolved spontaneously. He lives independently and returned from his grandparents' farm 2 days ago. He commonly consumes canned vegetables and fruits. He is alert and oriented to person, place, and time. His temperature is 37°C (98.6°F), pulse is 88/min, respirations are 10/min and labored, and blood pressure is 110/70 mm Hg. Examination shows bilateral nystagmus and ptosis. The pupils are dilated and not reactive to light. Muscle strength of the facial muscles and bilateral upper extremities is decreased. Upper extremity deep tendon reflexes are 1+ bilaterally. Cardiopulmonary examination shows no abnormalities. Which of the following is the most likely cause for this patient's symptoms?
Q213
A 17-year-old boy presents to the office with allergic rhinitis. He reports symptoms of sneezing, nasal congestion, itching, and postnasal drainage every September at the start of the school year. He has a family history of childhood asthma and eczema. He has not tried any medications for his allergies. Which of the following medications is the most appropriate next step to manage the patient's symptoms?
Q214
A 41-year-old woman with subclinical hypothyroidism comes to the physician because of a 6-month history of progressively worsening headaches and irregular menses. Her menses had previously occurred at regular 30-day intervals with moderate flow, but her last menstrual period was 12 weeks ago. She also reports that her interest in sexual intercourse has recently decreased. Her serum prolactin level is elevated. Which of the following is the most appropriate pharmacotherapy for this patient?
Q215
A 4-year-old boy with a history of cerebral palsy is brought to the neurology clinic by his mother with progressive tightness in the lower extremities. Although the patient has been intermittently undergoing physiotherapy for the past 2 years at a specialized center, the patient’s mother is concerned he cannot yet climb the stairs. The neurologist recommends a different treatment, which involves multiple intramuscular injections of a drug in the muscles of the lower extremities to relieve tightness. The neurologist says this treatment approach is also often used to relieve headaches and reduce facial wrinkles. Which of the following is most likely the mechanism of action of this drug?
Q216
A 63-year-old woman presents to her primary care doctor with increased urinary frequency. She has noticed that over the past 6 months, she has had to urinate more often than usual. Several times per day, she develops a rapid-onset need to urinate and has occasionally been unable to reach the restroom. These symptoms have caused her a lot of distress and impacted her work as a grocery store clerk. She has tried pelvic floor exercises, decreasing her caffeine consumption, and has intentionally lost 20 pounds in an effort to alleviate her symptoms. She denies urinary hesitancy or hematuria. Her past medical history is notable for rheumatoid arthritis for which she takes methotrexate. She does not smoke or drink alcohol. Her temperature is 98.8°F (37.1°C), blood pressure is 124/68 mmHg, pulse is 89/min, and respirations are 19/min. She is well-appearing and in no acute distress. Which of the following interventions would be most appropriate in this patient?
Q217
A 25-year-old man is brought to the emergency department 3 hours after rescuing babies and puppies from a burning daycare center. He complains of headache and nausea, which he attributes to running. He is breathing comfortably. What is another likely finding in this patient?
Q218
A 7-year-old boy is brought to the physician because of spells of unresponsiveness and upward rolling of the eyes for 2 months. The episodes start abruptly and last a few seconds. During that time he does not hear anyone’s voice or make any purposeful movements. When the episodes end, he continues what he was doing before the spell. He does not lose his posture or fall to the ground. Episodes occur multiple times during the day. Physical examination shows no abnormal findings. An EEG following hyperventilation shows 3 Hz spike-and-slow-wave discharges. Which of the following is the most appropriate pharmacotherapy at this time?
Q219
A 34-year-old man presents to the outpatient clinic with a complaint of right-sided jaw pain. The onset of pain was approx. 1 month ago and he is experiencing symptoms 2–3 times a day. Each episode of pain lasts for about 30 seconds. He describes the pain as severe (9 out of 10) with an electric and sharp quality. He denies having tear production or conjunctival injection on the affected side during attacks. What is the mechanism of action for the drug that will best treat this patient’s condition?
Q220
A new drug is designed to treat asthma by inhibiting bronchoconstriction. Experimental assays show that treated animals had markedly reduced acetylcholine binding to muscarinic receptors relative to untreated controls. The drug is most similar to which of the following:
Cholinergic/Adrenergic drugs US Medical PG Practice Questions and MCQs
Question 211: A 28-year-old woman presents with weight gain and a milky-white discharge from her breasts. Patient says she noticed herself gaining weight and a milky white discharge from her breasts. Past medical history is significant for schizophrenia, recently diagnosed and treated with risperidone. No history of headache, nausea, and vomiting. No other current medications. Her last menstrual period was 2 months ago. Review of systems is significant for decreased libido. Patient is afebrile and vital signs are within normal limits. On physical examination, patient had a weight gain of 3 kg (6.6 lb) over the past month. There is bilateral breast tenderness present. A urine pregnancy test is negative. Which of the following is the most likely etiology of this patient’s symptoms?
A. Increase in dopamine activity in mesolimbic pathway
B. Decrease in dopamine activity in mesolimbic pathway
C. Decrease in dopamine activity in tuberoinfundibular pathway (Correct Answer)
D. Decrease in dopamine activity in nigrostriatal pathway
E. Increase in dopamine activity in tuberoinfundibular pathway
Explanation: ***Decrease in dopamine activity in tuberoinfundibular pathway***
- The patient is taking **risperidone**, an antipsychotic that blocks **dopamine D2 receptors**. This blockade in the **tuberoinfundibular pathway** leads to increased prolactin secretion.
- Elevated **prolactin** levels cause **galactorrhea** (milky discharge), **amenorrhea** (missed periods), **weight gain**, and **decreased libido**.
*Increase in dopamine activity in mesolimbic pathway*
- An **increase in dopamine activity** in the **mesolimbic pathway** is associated with the positive symptoms of **schizophrenia** (e.g., hallucinations, delusions).
- Antipsychotics like risperidone aim to decrease this activity, not increase it, and this pathway is not directly involved in prolactin regulation.
*Decrease in dopamine activity in mesolimbic pathway*
- A **decrease in dopamine activity** in the **mesolimbic pathway** is the desired therapeutic effect of antipsychotics like risperidone, reducing psychotic symptoms.
- While it explains the treatment of schizophrenia, it does not explain the specific side effects of hyperprolactinemia.
*Decrease in dopamine activity in nigrostriatal pathway*
- A **decrease in dopamine activity** in the **nigrostriatal pathway** is responsible for **extrapyramidal symptoms** (EPS) such as parkinsonism (tremor, rigidity), akathisia, and dystonia.
- While antipsychotics can cause EPS, these are not the predominant symptoms (galactorrhea, weight gain, amenorrhea) described in the patient.
*Increase in dopamine activity in tuberoinfundibular pathway*
- An **increase in dopamine activity** in the **tuberoinfundibular pathway** would lead to a decrease in prolactin secretion, as dopamine is a **prolactin-inhibiting hormone**.
- This would result in symptoms opposite to what the patient is experiencing, such as no galactorrhea or even hypoprolactinemia.
Question 212: A 26-year-old man is brought to the emergency department by his friends because of blurred vision and slurred speech for the past 6 hours. He had some difficulty swallowing his food during lunch and has weakness in both arms. Two weeks ago, he had an upper respiratory infection that resolved spontaneously. He lives independently and returned from his grandparents' farm 2 days ago. He commonly consumes canned vegetables and fruits. He is alert and oriented to person, place, and time. His temperature is 37°C (98.6°F), pulse is 88/min, respirations are 10/min and labored, and blood pressure is 110/70 mm Hg. Examination shows bilateral nystagmus and ptosis. The pupils are dilated and not reactive to light. Muscle strength of the facial muscles and bilateral upper extremities is decreased. Upper extremity deep tendon reflexes are 1+ bilaterally. Cardiopulmonary examination shows no abnormalities. Which of the following is the most likely cause for this patient's symptoms?
A. Autoantibodies against myelin
B. Chemical that inhibits acetylcholinesterase
C. Autoantibodies against ACh receptors
D. Toxin that inhibits ACh release (Correct Answer)
E. Cell-mediated focal demyelination
Explanation: **Toxin that inhibits ACh release**
- The patient's symptoms, including **blurred vision, ptosis, fixed dilated pupils, slurred speech, dysphagia, and descending flaccid paralysis** (weakness in arms before legs, with reduced reflexes), are highly characteristic of **botulism**.
- **Clostridium botulinum toxin** inhibits the release of **acetylcholine (ACh)** at the neuromuscular junction and parasympathetic synapses, leading to these symptoms. The history of consuming **canned foods** and returning from a farm suggests a potential exposure source.
*Autoantibodies against myelin*
- This mechanism describes **Guillain-Barré syndrome (GBS)**, which typically presents with **ascending paralysis** and areflexia, often following an infection.
- While GBS can cause some cranial nerve involvement, the prominent **fixed dilated pupils (pupil-sparing paralysis is typical in GBS)** and the **descending pattern of weakness** in this patient are inconsistent with GBS.
*Chemical that inhibits acetylcholinesterase*
- This mechanism is associated with **organophosphate poisoning**, which presents with a **cholinergic crisis**.
- Symptoms include **miosis**, increased salivation, lacrimation, urination, defecation, gastrointestinal upset, emesis (**SLUDGE** syndrome), bradycardia, and muscle fasciculations, none of which are noted in this patient.
*Autoantibodies against ACh receptors*
- This is the underlying mechanism of **myasthenia gravis**, an autoimmune disorder characterized by **fluctuating muscle weakness** that worsens with activity and improves with rest.
- Key features often include **ptosis and diplopia**, but pupils are typically **spared**. The weakness in myasthenia gravis is not typically descending with fixed dilated pupils, and it does not usually present acutely with such severe widespread involvement.
*Cell-mediated focal demyelination*
- This describes the pathology of **multiple sclerosis (MS)**, a chronic inflammatory demyelinating disease of the central nervous system.
- MS typically presents with **diverse neurological symptoms** that can be relapsing-remitting or progressive, often including sensory disturbances, motor weakness, visual changes (e.g., optic neuritis), and bladder dysfunction. It does not typically cause acute, rapidly progressive flaccid paralysis with fixed dilated pupils and bulbar symptoms as seen here.
Question 213: A 17-year-old boy presents to the office with allergic rhinitis. He reports symptoms of sneezing, nasal congestion, itching, and postnasal drainage every September at the start of the school year. He has a family history of childhood asthma and eczema. He has not tried any medications for his allergies. Which of the following medications is the most appropriate next step to manage the patient's symptoms?
A. Intranasal cromolyn sodium
B. Intranasal decongestants
C. Oral antihistamines
D. Intranasal antihistamines
E. Intranasal corticosteroids (Correct Answer)
Explanation: ***Intranasal corticosteroids***
- Are considered **first-line treatment** for persistent allergic rhinitis due to their broad anti-inflammatory effects, effectively reducing sneezing, congestion, itching, and postnasal drip.
- They provide **superior symptom control** compared to other medications for moderate-to-severe symptoms, which this patient appears to have based on the regular occurrence and multiple symptoms.
*Intranasal cromolyn sodium*
- This is a **mast cell stabilizer** that prevents the release of inflammatory mediators, but it is less potent than corticosteroids.
- It requires **frequent dosing** (3-4 times daily) and is generally reserved for patients with mild, intermittent symptoms or as an adjunct therapy.
*Intranasal decongestants*
- Provide temporary relief for **nasal congestion** but do not address other symptoms like sneezing or itching.
- Long-term use (more than 3-5 days) can lead to **rhinitis medicamentosa** (rebound congestion), making them unsuitable for chronic seasonal allergies.
*Oral antihistamines*
- Are effective for sneezing, itching, and rhinorrhea but are generally **less effective for nasal congestion** and postnasal drip compared to intranasal corticosteroids.
- Second-generation oral antihistamines (e.g., loratadine, fexofenadine) are preferred over first-generation due to **less sedation**.
*Intranasal antihistamines*
- Provide rapid relief for sneezing, itching, and rhinorrhea and can be more effective than oral antihistamines for nasal symptoms.
- However, they are **less effective for nasal congestion** and postnasal drip compared to intranasal corticosteroids, which address the wider inflammatory response.
Question 214: A 41-year-old woman with subclinical hypothyroidism comes to the physician because of a 6-month history of progressively worsening headaches and irregular menses. Her menses had previously occurred at regular 30-day intervals with moderate flow, but her last menstrual period was 12 weeks ago. She also reports that her interest in sexual intercourse has recently decreased. Her serum prolactin level is elevated. Which of the following is the most appropriate pharmacotherapy for this patient?
A. Methyldopa
B. Estrogen
C. L-thyroxine
D. Bromocriptine (Correct Answer)
E. Metoclopramide
Explanation: ***Bromocriptine***
- The patient's symptoms (headaches, irregular menses, decreased libido) coupled with an **elevated serum prolactin level** are indicative of **hyperprolactinemia**, likely due to a pituitary adenoma (prolactinoma).
- **Bromocriptine** is a **dopamine agonist** that effectively reduces prolactin secretion by stimulating dopamine D2 receptors in the pituitary, leading to resolution of symptoms and potential shrinkage of prolactinomas.
- This is the **first-line pharmacotherapy** for prolactinomas.
*Methyldopa*
- **Methyldopa** is an **antihypertensive medication** that works by stimulating central alpha-2 adrenergic receptors.
- It is not indicated for the treatment of hyperprolactinemia; in fact, **methyldopa can cause hyperprolactinemia** as a side effect.
*Estrogen*
- **Estrogen** therapy is sometimes used in women with irregular menses, but it would not address the underlying hyperprolactinemia.
- In fact, **estrogen can stimulate prolactin secretion**, potentially worsening the condition and should be avoided in patients with prolactinomas.
*L-thyroxine*
- **L-thyroxine** is used to treat **hypothyroidism**, which the patient has (subclinical), but it will not directly address the symptoms related to hyperprolactinemia (headaches, irregular menses, elevated prolactin).
- While severe primary hypothyroidism can sometimes cause secondary hyperprolactinemia via TRH stimulation, this patient's **subclinical hypothyroidism** is unlikely to be the primary cause of her significantly elevated prolactin and symptoms.
- The **most appropriate therapy** targets the hyperprolactinemia directly.
*Metoclopramide*
- **Metoclopramide** is a **dopamine antagonist** used as an antiemetic and prokinetic agent.
- It **increases prolactin secretion** by blocking dopamine D2 receptors in the pituitary, which would significantly exacerbate the patient's hyperprolactinemia.
Question 215: A 4-year-old boy with a history of cerebral palsy is brought to the neurology clinic by his mother with progressive tightness in the lower extremities. Although the patient has been intermittently undergoing physiotherapy for the past 2 years at a specialized center, the patient’s mother is concerned he cannot yet climb the stairs. The neurologist recommends a different treatment, which involves multiple intramuscular injections of a drug in the muscles of the lower extremities to relieve tightness. The neurologist says this treatment approach is also often used to relieve headaches and reduce facial wrinkles. Which of the following is most likely the mechanism of action of this drug?
A. Interferes with the 60s ribosomal subunit
B. Blocks the release of acetylcholine (Correct Answer)
C. Reduces neurotransmitter GABA
D. Acts as a superantigen
E. Stimulates adenylate cyclase
Explanation: ***Blocks the release of acetylcholine***
- The scenario describes **botulinum toxin**, which is used to treat **spasticity** in cerebral palsy, as well as for cosmetic purposes (reducing facial wrinkles) and chronic migraine prophylaxis
- Botulinum toxin works by **cleaving SNARE proteins** (synaptobrevin, syntaxin, SNAP-25) necessary for fusion of acetylcholine-containing vesicles with the presynaptic membrane
- This prevents **acetylcholine release** at the neuromuscular junction, causing localized muscle paralysis and relieving spasticity
- The drug is administered via **multiple intramuscular injections** directly into affected muscles
*Interferes with the 60s ribosomal subunit*
- This mechanism is associated with certain **antibiotics** like macrolides (erythromycin) or clindamycin, which inhibit bacterial protein synthesis
- Not relevant to muscle spasticity treatment or the described clinical uses
*Reduces neurotransmitter GABA*
- Drugs that reduce **GABAergic signaling** would increase neuronal excitability and potentially worsen muscle tone
- This would **exacerbate spasticity**, not relieve it
- Examples include flumazenil (GABA antagonist)
*Acts as a superantigen*
- **Superantigens** are bacterial toxins (e.g., from Staphylococcus aureus, Streptococcus pyogenes) that stimulate massive, non-specific T-cell activation
- Lead to conditions like toxic shock syndrome
- Completely unrelated to the mechanism for treating muscle spasticity
*Stimulates adenylate cyclase*
- Stimulation of **adenylate cyclase** increases intracellular cAMP levels
- This is the mechanism of various drugs including beta-adrenergic agonists and certain hormones
- Not associated with the localized muscle relaxation achieved by botulinum toxin
Question 216: A 63-year-old woman presents to her primary care doctor with increased urinary frequency. She has noticed that over the past 6 months, she has had to urinate more often than usual. Several times per day, she develops a rapid-onset need to urinate and has occasionally been unable to reach the restroom. These symptoms have caused her a lot of distress and impacted her work as a grocery store clerk. She has tried pelvic floor exercises, decreasing her caffeine consumption, and has intentionally lost 20 pounds in an effort to alleviate her symptoms. She denies urinary hesitancy or hematuria. Her past medical history is notable for rheumatoid arthritis for which she takes methotrexate. She does not smoke or drink alcohol. Her temperature is 98.8°F (37.1°C), blood pressure is 124/68 mmHg, pulse is 89/min, and respirations are 19/min. She is well-appearing and in no acute distress. Which of the following interventions would be most appropriate in this patient?
A. Intermittent catheterization
B. Tamsulosin
C. Topical estrogen
D. Pessary placement
E. Oxybutynin (Correct Answer)
Explanation: ***Oxybutynin***
- The patient presents with classic symptoms of **overactive bladder**, including increased urinary frequency, urgency, and urge incontinence, which have not responded to behavioral modifications. Oxybutynin is an **antimuscarinic medication** that relaxes the detrusor muscle, reducing bladder spasms and urgency.
- This medication is a **first-line pharmacological treatment** for overactive bladder syndrome after conservative therapies have failed, making it the most appropriate intervention given her symptoms and history.
*Intermittent catheterization*
- This intervention is primarily used for **urinary retention** or significant **post-void residual volume**, which are not indicated by the patient's symptoms (she denies urinary hesitancy).
- Her symptoms are consistent with bladder overactivity, not an inability to empty her bladder, so catheterization would be inappropriate and potentially harmful.
*Tamsulosin*
- Tamsulosin is an **alpha-1 adrenergic blocker** typically used to treat symptoms of **benign prostatic hyperplasia (BPH)** in men by relaxing smooth muscle in the prostate and bladder neck.
- It is not indicated for overactive bladder in women and would not address her primary symptoms of frequency and urgency.
*Topical estrogen*
- Topical estrogen can be beneficial for **urogenital atrophy** in postmenopausal women, which can contribute to urinary symptoms, particularly stress incontinence or dysuria.
- While she is a 63-year-old woman, her symptoms are clearly indicative of **urge incontinence** and overactive bladder, which are less likely to be solely improved by estrogen, especially given the severity and associated urgency.
*Pessary placement*
- Pessaries are used for **pelvic organ prolapse** or **stress urinary incontinence** to provide structural support or compress the urethra.
- The patient's primary complaint is **urge incontinence** and overactive bladder symptoms, not prolapse or stress incontinence, making a pessary an unsuitable intervention.
Question 217: A 25-year-old man is brought to the emergency department 3 hours after rescuing babies and puppies from a burning daycare center. He complains of headache and nausea, which he attributes to running. He is breathing comfortably. What is another likely finding in this patient?
A. Oxygen saturation of 86% on pulse oximetry
B. Low blood lactate levels
C. Arterial oxygen partial pressure of 20 mmHg
D. Oxygen saturation of 99% on pulse oximetry
E. Cherry red facial appearance (Correct Answer)
Explanation: ***Cherry red facial appearance***
- The patient's presentation after being in a burning building strongly suggests **carbon monoxide (CO) poisoning**. CO binds to hemoglobin with higher affinity than oxygen, forming **carboxyhemoglobin**, which gives the skin and mucous membranes a characteristic **cherry-red (plethoric) appearance**, though this is often only seen in severe cases or post-mortem.
- Other symptoms like **headache and nausea** are classic for CO poisoning, often mistaken for other mild ailments or exertion.
*Oxygen saturation of 86% on pulse oximetry*
- While a low oxygen saturation is concerning, **pulse oximetry readings are unreliable in carbon monoxide poisoning** because standard pulse oximeters cannot differentiate between oxyhemoglobin and carboxyhemoglobin.
- A patient with significant CO poisoning can have a high pulse oximetry reading even with severe hypoxemia at the tissue level, making this an unlikely and misleading finding.
*Low blood lactate levels*
- **Carbon monoxide poisoning** leads to **tissue hypoxia**, which switches cellular metabolism from aerobic to anaerobic glycolysis.
- This results in the overproduction of **lactate**, leading to **elevated blood lactate levels**, not low levels.
*Arterial oxygen partial pressure of 20 mmHg*
- A **PaO2 of 20 mmHg** is severely low and would indicate extreme hypoxemia, which would likely present with significant respiratory distress or altered mental status, and a pulse oximetry reading would be reflective of this severe hypoxemia.
- In **carbon monoxide poisoning**, the PaO2 is typically normal because oxygen can still dissolve in the plasma, but its transport and offloading are impaired by carboxyhemoglobin.
*Oxygen saturation of 99% on pulse oximetry*
- A pulse oximeter measures the percentage of hemoglobin saturated with oxygen. However, it cannot distinguish between **oxyhemoglobin** and **carboxyhemoglobin**.
- Therefore, in CO poisoning, pulse oximetry may give a **falsely high or normal reading (e.g., 99%)**, even when the patient is severely hypoxic due to CO.
Question 218: A 7-year-old boy is brought to the physician because of spells of unresponsiveness and upward rolling of the eyes for 2 months. The episodes start abruptly and last a few seconds. During that time he does not hear anyone’s voice or make any purposeful movements. When the episodes end, he continues what he was doing before the spell. He does not lose his posture or fall to the ground. Episodes occur multiple times during the day. Physical examination shows no abnormal findings. An EEG following hyperventilation shows 3 Hz spike-and-slow-wave discharges. Which of the following is the most appropriate pharmacotherapy at this time?
A. No pharmacotherapy at this time
B. Ethosuximide (Correct Answer)
C. Sodium valproate
D. Oxcarbazepine
E. Lamotrigine
Explanation: ***Ethosuximide***
- The described clinical picture (brief unresponsiveness, eye-rolling, continuing activity afterward, frequent daily episodes, normal physical exam, and 3-Hz spike-and-slow-wave discharges on EEG during hyperventilation) is classic for **childhood absence epilepsy**.
- **Ethosuximide** is the first-line and most effective treatment specifically for absence seizures due to its selective action on T-type calcium channels in the thalamus, which are implicated in the generation of absence seizures.
*No pharmacotherapy at this time*
- Leaving childhood absence epilepsy untreated can lead to significant impairments in learning, attention, and cognitive development due to the frequent, brief interruptions in consciousness.
- Given the clear diagnostic criteria including characteristic EEG findings and frequent episodes, initiating appropriate pharmacotherapy is medically indicated and crucial for the child's well-being.
*Sodium valproate*
- While **sodium valproate** is effective against absence seizures and has a broader spectrum of action against other seizure types, it is often considered a second-line agent for absence epilepsy due to potential side effects.
- Its use may be preferred if there are co-occurring generalized tonic-clonic seizures or if ethosuximide is not tolerated or effective, but for isolated absence seizures, ethosuximide has a better side effect profile.
*Oxcarbazepine*
- **Oxcarbazepine** is a sodium channel blocker primarily used for focal (partial onset) seizures and secondarily generalized tonic-clonic seizures.
- It is generally ineffective and can sometimes *worsen* absence seizures, making it an inappropriate choice for this diagnosis.
*Lamotrigine*
- **Lamotrigine** is a broad-spectrum antiepileptic drug effective for various seizure types, including focal, generalized tonic-clonic, and some forms of atypical absence seizures.
- While it can be used for absence seizures, it is generally considered a second-line or add-on therapy, especially when ethosuximide or valproate are ineffective or not tolerated, or if there are co-existing seizure types. It is not the most appropriate first-line choice for classic childhood absence epilepsy.
Question 219: A 34-year-old man presents to the outpatient clinic with a complaint of right-sided jaw pain. The onset of pain was approx. 1 month ago and he is experiencing symptoms 2–3 times a day. Each episode of pain lasts for about 30 seconds. He describes the pain as severe (9 out of 10) with an electric and sharp quality. He denies having tear production or conjunctival injection on the affected side during attacks. What is the mechanism of action for the drug that will best treat this patient’s condition?
A. Increase the time of Cl- channel opening
B. Prevention of Na+ influx (Correct Answer)
C. Decrease the excitatory effects of glutamic acid
D. Decrease in the Ca2+ influx
E. Increase the frequency of Cl- channel opening
Explanation: ***Prevention of Na+ influx***
- The patient's symptoms (right-sided jaw pain, severe, electric, sharp quality, short duration, triggered by daily activities like chewing/talking) are highly consistent with **trigeminal neuralgia**.
- **Carbamazepine**, a sodium channel blocker, is the first-line treatment for trigeminal neuralgia, and its mechanism of action involves **preventing Na+ influx** in neural membranes, thus stabilizing the excited nerve.
*Increase the time of Cl- channel opening*
- This mechanism is associated with **benzodiazepines**, which act on GABA-A receptors to enhance the inhibitory effects of GABA by **increasing the duration of Cl- channel opening**.
- While benzodiazepines can have anticonvulsant properties, they are not the primary treatment for trigeminal neuralgia because **carbamazepine is more effective** at specifically targeting the hyperexcitability of the trigeminal nerve.
*Decrease the excitatory effects of glutamic acid*
- This mechanism is characteristic of drugs like **memantine** (used in Alzheimer's disease) or some antiglutamatergic agents in epilepsy.
- While glutamatergic overactivity can contribute to pain, **inhibiting glutamate receptors** is not the primary or most effective strategy for the acute symptomatic relief in trigeminal neuralgia.
*Decrease in the Ca2+ influx*
- This mechanism is seen with **calcium channel blockers** like gabapentin and pregabalin, which can be used as second-line treatments for neuropathic pain including trigeminal neuralgia.
- However, **sodium channel blockade** (e.g., carbamazepine) is considered more direct and effective for the high-frequency firing characteristic of trigeminal neuralgia.
*Increase the frequency of Cl- channel opening*
- This mechanism also involves **GABA-A receptor agonists** like benzodiazepines, but specifically some agents might increase the frequency of chloride channel opening rather than duration or both.
- Similar to increasing the time of Cl- channel opening, this mechanism aims to enhance GABAergic inhibition but is **not the primary mechanism of action** for the most effective drug in trigeminal neuralgia.
Question 220: A new drug is designed to treat asthma by inhibiting bronchoconstriction. Experimental assays show that treated animals had markedly reduced acetylcholine binding to muscarinic receptors relative to untreated controls. The drug is most similar to which of the following:
A. Theophylline
B. Cromolyn
C. Zafirlukast
D. Prednisone
E. Ipratropium (Correct Answer)
Explanation: ***Ipratropium***
- This drug works as a **muscarinic acetylcholine receptor antagonist**, blocking the bronchoconstrictive effects of acetylcholine release in the airways.
- The experimental assay showing reduced **acetylcholine binding to muscarinic receptors** directly mimics the mechanism of action of ipratropium.
*Theophylline*
- Theophylline is a **phosphodiesterase inhibitor**, leading to increased cyclic AMP and bronchodilation, but it does not directly interfere with acetylcholine binding to muscarinic receptors.
- Its mechanism also involves adenosine receptor antagonism.
*Cromolyn*
- Cromolyn is a **mast cell stabilizer** that prevents the release of inflammatory mediators like histamine, thereby preventing bronchoconstriction.
- It does not act on muscarinic receptors.
*Zafirlukast*
- Zafirlukast is a **leukotriene receptor antagonist**, blocking the actions of leukotrienes which are potent bronchoconstrictors and pro-inflammatory mediators.
- Its mechanism is distinct from muscarinic receptor antagonism.
*Prednisone*
- Prednisone is a **corticosteroid** that reduces inflammation by inhibiting the synthesis of inflammatory mediators and altering gene expression.
- It does not directly affect acetylcholine binding at muscarinic receptors.